35,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Lansdowne Partners UK LLP

Lansdowne Partners UK LLP purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 35,000 shares of the company's stock, valued at approximately $1,455,000. Moderna comprises 0.1% of Lansdowne Partners UK LLP's investment portfolio, making the stock its 17th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wilmington Savings Fund Society FSB boosted its holdings in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the 4th quarter valued at $37,000. Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

Shares of MRNA traded down $0.48 during mid-day trading on Thursday, reaching $24.72. 6,678,250 shares of the company's stock traded hands, compared to its average volume of 7,227,182. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The stock has a market cap of $9.56 billion, a P/E ratio of -2.66 and a beta of 2.23. The stock's 50-day moving average is $31.10 and its two-hundred day moving average is $40.37.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Berenberg Bank lifted their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday, January 16th. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Finally, Evercore ISI set a $50.00 target price on shares of Moderna in a research note on Friday, February 14th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Moderna currently has a consensus rating of "Hold" and a consensus target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.